HeartFlow Announces New Decision from Centers for Medicare & Medicaid Services Boosting CCTA Reimbursement and Access
Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans for patients with coronary artery disease
FFRCT further validated in additional study demonstrating diagnostic accuracy and greater ability to rule out hemodynamically significant stenoses versus CCTA in patients with high-risk NSTE-ACS
Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024
Data confirm the use of FFRCT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans for patients with coronary artery disease
FFRCT further validated in additional study demonstrating diagnostic accuracy and greater ability to rule out hemodynamically significant stenoses versus CCTA in patients with high-risk NSTE-ACS
HeartFlow Announces New Category I CPT Code from the American Medical Association for AI-Enabled Plaque Analysis to Assess Risk for Coronary Artery Disease
New reimbursement code follows recent favorable Medicare coverage decision, expanding access to HeartFlow’s Plaque Analysis to help physicians provide personalized treatment plans.
HeartFlow to Present Latest Data on AI-Enabled Coronary Artery Disease Management at TCT 2024
Long-term outcomes data from ADVANCE-DK Registry with HeartFlow FFRCT and Plaque Analysis and ongoing clinical studies highlighting CCTA and FFRCT diagnostic pathway to be discussed in six presentations
HeartFlow Announces Favorable Coverage Determination for Plaque Analysis by Five Medicare Administrative Contractors
Coverage policy improves access to artificial intelligence-enabled plaque analysis providing insights to help physicians guide treatment decisions for patients with coronary artery disease
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography
SCCT 2024: HeartFlow to Present New Data on Coronary Artery Disease Management with Coronary Computed Tomography Angiography MOUNTAIN VIEW, Calif. – July 16, 2024 – HeartFlow, a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced it will be presenting new findings on the use of coronary computed tomography angiography (coronary CTA) […]
HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease
HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease Technology offers benefits of HeartFlow Plaque Analysis with the new addition of 3D interactive capabilities, integrated with lesion specific FFRCT values WASHINGTON, D.C. — July 18, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) […]
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage
HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage Coverage policy determination initiated with 5 Medicare MACs for HeartFlow’s AI-QCT revolutionizing cardiovascular care for patients MOUNTAIN VIEW, Calif. – June 3, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for […]
HeartFlow’s Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study
HeartFlow’s Plaque Analysis Leading The Way: 95% Accuracy vs Invasive Imaging In Newly Published REVEALPLAQUE Study MOUNTAIN VIEW, Calif. – May 15, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that the data from its REVEALPLAQUE study, highlighting the accuracy of its Plaque Analysis, was published in […]
HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients
HeartFlow Announces Revolutionary Five-Year Data Demonstrating a 63 Percent Mortality Reduction with FFRCT-Guided Care in PAD Patients First published evidence: FFRCT-guided diagnosis and treatment drastically reduces mortality in peripheral artery disease (PAD) patients MOUNTAIN VIEW, Calif. – May 8, 2024 — In a groundbreaking development, a study published in the Journal of Vascular Surgery reveals […]
